Non-Hodgkin Lymphoma: Initial Work-Up and First-Line Therapy
Diagnosis and Staging
Diagnosis must be established by excisional lymph node biopsy or surgical specimen—core biopsies are acceptable only when lymph nodes are inaccessible (e.g., retroperitoneal), and fine needle aspiration is inadequate for reliable diagnosis 1. The pathology report must classify the lymphoma according to WHO criteria, as treatment differs fundamentally between subtypes.
Essential Diagnostic Work-Up
Complete staging evaluation includes:
- CT scan of chest and abdomen (minimum requirement) 2
- Bone marrow aspirate and biopsy 2
- Complete blood count and blood chemistry including LDH, uric acid 2
- Screening for HIV, hepatitis B and C 2
- Performance status assessment and cardiac function (left ventricular ejection fraction) before anthracycline therapy 2
- PET-CT can better delineate disease extent and evaluate treatment response 2
For high-risk patients (>2 adverse IPI parameters, bone marrow/testis/spine/skull base involvement), perform diagnostic lumbar puncture with prophylactic intrathecal cytarabine or methotrexate 2.
Stage according to Ann Arbor/Lugano classification and calculate International Prognostic Index (IPI) for prognostication 2.
First-Line Treatment by Subtype
Diffuse Large B-Cell Lymphoma (DLBCL)
R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard first-line therapy for all CD20+ DLBCL patients 2.
Treatment Algorithm:
Young patients (≤60 years) with low risk (age-adjusted IPI ≤1):
- 6-8 cycles R-CHOP every 21 days with 8 doses of rituximab [I, A] 2
Young patients with high risk (age-adjusted IPI ≥2):
- 6-8 cycles R-CHOP every 14-21 days with 8 doses of rituximab 2
- CNS prophylaxis is mandatory in high-risk patients 2
- Consider clinical trials, as standard therapy has insufficient efficacy 2
Patients >60 years:
- 8 cycles R-CHOP every 21 days with 8 doses of rituximab [I, A] 2
- If R-CHOP given every 14 days, 6 cycles are sufficient 2
Critical pitfall: Avoid dose reductions for hematological toxicity—use prophylactic growth factors for febrile neutropenia instead 2. In high tumor burden cases, initiate corticosteroid pre-phase to prevent tumor lysis syndrome 2.
Follicular Lymphoma
Treatment depends entirely on stage and symptom burden.
Stage I-II (limited disease):
- Radiotherapy (involved or extended field, 30-40 Gy) is the treatment of choice with curative potential [II, B] 1, 3
- For large tumor burden, apply systemic therapy before radiation 1, 3
Stage III-IV (advanced disease):
Asymptomatic patients with low tumor burden:
- Watch-and-wait is the standard approach [I, A] 3
- No curative therapy exists; spontaneous regressions occur in 15-20% 1, 3
Symptomatic patients (B symptoms, cytopenias, bulky disease, vital organ compression, rapid progression):
- Obinutuzumab or rituximab combined with CHOP or bendamustine [I, B] 3
- For aggressive clinical course, prefer obinutuzumab/rituximab-CHOP 3
- Rituximab maintenance every 2 months for 2 years after immunochemotherapy is recommended [I, B] 3
- Alternative: radioimmunotherapy consolidation after chemotherapy [II, B] 3
Important: Extended anti-infectious prophylaxis should be considered after bendamustine-containing therapy 3. For hepatitis B-positive patients (including occult carriers), prophylactic antiviral medication up to 2 years beyond last rituximab exposure is mandatory [I, A] 3.
Mantle Cell Lymphoma
Stage I-II (rare):
- Shortened conventional chemotherapy followed by consolidation radiotherapy (30-36 Gy) 4
- For large tumor burden or adverse features, use systemic therapy as for advanced stages 4
Stage III-IV:
Elderly patients (not transplant candidates):
- Immunochemotherapy (e.g., R-CHOP, bendamustine-rituximab, R-BAC) 4
- Rituximab maintenance significantly improves PFS and OS after R-CHOP [I, A] 4
Younger patients (transplant eligible):
- Intensive immunochemotherapy including cytarabine-containing regimens 4
- Consolidation with autologous stem cell transplantation 4
Calculate MIPI-c score for prognostication [I, A] 4. A subset with leukaemic non-nodal presentation, splenomegaly, SOX11 negativity, and low Ki-67 may have indolent behavior—short watch-and-wait under close observation is appropriate [III, B] 4.
Response Evaluation
Repeat imaging after 3-4 cycles and after completion of therapy 2. Bone marrow biopsy should be repeated only at end of treatment if initially involved 2.
PET-CT after completion of induction has prognostic value but therapeutic consequences remain undefined—histological confirmation of PET positivity is strongly recommended before changing therapy 2, 3.
Key Pitfalls to Avoid
- Never use fine needle aspiration for initial diagnosis—inadequate for reliable classification 1
- Do not reduce chemotherapy doses for hematological toxicity—use growth factor support instead 2
- Do not omit CNS prophylaxis in high-risk DLBCL patients 2
- Always obtain repeat biopsy at relapse to exclude transformation to aggressive lymphoma 3
- Do not forget hepatitis B prophylaxis with rituximab—reactivation can be fatal 3